{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:12:38Z","timestamp":1788797558617,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this study is to determine the most cost-effective strategy for the treatment of primary open-angle glaucoma (POAG) in Brazil, from the payer's perspective (Brazilian Public Health System) in the setting of the Glaucoma Referral Centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Study design was a cost-effectiveness analysis of different treatment strategies for POAG. We developed 3 Markov models (one for each glaucoma stage: early, moderate and advanced), using a hypothetical cohort of POAG patients, from the perspective of the Brazilian Public Health System (SUS) and a horizon of the average life expectancy of the Brazilian population. Different strategies were tested according to disease severity. For early glaucoma, we compared observation, laser and medications. For moderate glaucoma, medications, laser and surgery. For advanced glaucoma, medications and surgery. Main outcome measures were ICER (incremental cost-effectiveness ratio), medical direct costs and QALY (quality-adjusted life year).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In early glaucoma, both laser and medical treatment were cost-effective (ICERs of initial laser and initial medical treatment over observation only, were R$ 2,811.39\/QALY and R$ 3,450.47\/QALY). Compared to observation strategy, the two alternatives have provided significant gains in quality of life. In moderate glaucoma population, medical treatment presented the highest costs among treatment strategies. Both laser and surgery were highly cost-effective in this group. For advanced glaucoma, both tested strategies were cost-effective. Starting age had a great impact on results in all studied groups. Initiating glaucoma therapy using laser or surgery were more cost-effective, the younger the patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>All tested treatment strategies for glaucoma provided real gains in quality of life and were cost-effective. However, according to the disease severity, not all strategies provided the same cost-effectiveness profile. Based on our findings, there should be a preferred strategy for each glaucoma stage, according to a cost-effectiveness ratio ranking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000005745","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T14:06:09Z","timestamp":1483020369000},"page":"e5745","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity"],"prefix":"10.1097","volume":"95","author":[{"given":"Ricardo Augusto Paletta","family":"Guedes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Maria Paletta","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo de Mello","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Chaoubah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-44-20260907","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/archopht.124.12.1754","article-title":"The economic burden of major adult visual disorders in the United States","volume":"124","author":"Rein","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R2-44-20260907","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0002-9394(02)02110-4","article-title":"The magnitude and cost of global blindness: an increasing problem that can be alleviated","volume":"135","author":"Frick","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R3-44-20260907","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.ophtha.2006.10.031","article-title":"Cost of patients with primary open-angle glaucoma. A retrospective study of commercial insurance claims data","volume":"114","author":"Lee","year":"2007","journal-title":"Ophthalmology"},{"key":"R4-44-20260907","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archopht.124.1.12","article-title":"A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma","volume":"124","author":"Lee","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R5-44-20260907","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00019053-200725040-00003","article-title":"The economic implications of glaucoma: a literature review","volume":"25","author":"Schmier","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"R6-44-20260907","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.3390\/ijerph6122950","article-title":"Health economic assessment: a methodological primer","volume":"6","author":"Simoens","year":"2009","journal-title":"Int J Environ Res Public Health"},{"key":"R8-44-20260907","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0161-6420(02)01437-9","article-title":"56,000 ways to treat glaucoma","volume":"109","author":"Realini","year":"2002","journal-title":"Ophthalmology"},{"key":"R10-44-20260907","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jcjo.2014.10.003","article-title":"Selective laser trabeculoplasty as a first-line therapy: a review","volume":"49","author":"Waisbourd","year":"2014","journal-title":"Can J Ophthalmol"},{"key":"R12-44-20260907","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1442-9071.2011.02530.x","article-title":"Economic impact of primary open angle glaucoma in Australia","volume":"39","author":"Dirani","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"key":"R13-44-20260907","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archophthalmol.2011.2727","article-title":"Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma","volume":"130","author":"Stein","year":"2012","journal-title":"Arch Opththamol"},{"key":"R14-44-20260907","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"key":"R15-44-20260907","first-page":"119","article-title":"Four-year cost-effectiveness of initial trabeculectomy versus conventional therapy in primary open angle glaucoma","volume":"44","author":"Yu","year":"2008","journal-title":"Value Health"},{"key":"R17-44-20260907","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/IJG.0b013e31824ceb8b","article-title":"Quality of life of medically versus surgically treated glaucoma patients","volume":"22","author":"Guedes","year":"2013","journal-title":"J Glaucoma"},{"key":"R19-44-20260907","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bjo.85.3.327","article-title":"Utility values associated with blindness in an adult population","volume":"85","author":"Brown","year":"2001","journal-title":"Br J Opthahlmol"},{"key":"R20-44-20260907","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ophtha.2007.06.008","article-title":"The impact of anchor points on utilities for 5 common ophthalmic diseases","volume":"115","author":"Lee","year":"2008","journal-title":"Ophthalmology"},{"key":"R23-44-20260907","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1185\/03007990802379996","article-title":"Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US","volume":"24","author":"Cantor","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R24-44-20260907","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1590\/S0004-27492011000600003","article-title":"Resources use, costs and effectiveness of non-penetrating deep sclerectomy according to glaucoma stage","volume":"74","author":"Guedes","year":"2011","journal-title":"Arq Bras Oftalmol"},{"key":"R25-44-20260907","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ophtha.2008.12.056","article-title":"The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United Stated","volume":"116","author":"Rein","year":"2009","journal-title":"Ophthalmology"},{"key":"R26-44-20260907","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R27-44-20260907","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/09286580701501931","article-title":"Open-angle glaucoma: an epidemiologic overview","volume":"14","author":"Leske","year":"2009","journal-title":"Ophthalmic Epidemiol"},{"key":"R28-44-20260907","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs. A meta-analysis of randomized clinical trials","volume":"112","author":"van der Valk","year":"2005","journal-title":"Ophthalmology"},{"key":"R30-44-20260907","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"Low-pressure glaucoma study group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study","volume":"151","author":"Krupin","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R31-44-20260907","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/OPTH.S92653","article-title":"Does the type of treatment have an influence on utility values in a glaucoma population?","volume":"9","author":"Paletta Guedes","year":"2015","journal-title":"Clin Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:03:22Z","timestamp":1788797002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":23,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005745","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}